WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2001080898) FULLERENE-BASED DRUGS TARGETED TO BONE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2001/080898    International Application No.:    PCT/US2001/013445
Publication Date: 01.11.2001 International Filing Date: 27.04.2001
Chapter 2 Demand Filed:    26.11.2001    
IPC:
A61K 47/48 (2006.01)
Applicants: WILSON, Lon, J. [US/US]; (US) (For US Only).
SAGMAN, Uri [CA/CA]; (CA) (For US Only).
GONZALES, Kelly, A. [US/US]; (US) (For US Only).
PRITZKER, Kenneth [US/CA]; (CA) (For US Only).
WM. MARSH RICE UNIVERSITY [US/US]; 6100 Main Street Houston, TX 77005 (US) (For All Designated States Except US)
Inventors: WILSON, Lon, J.; (US).
SAGMAN, Uri; (CA).
GONZALES, Kelly, A.; (US).
PRITZKER, Kenneth; (CA)
Agent: WATKINS, Marcella, D.; Conley, Rose & Tayon, P.C. P.O. Box 3267 Houston, TX 77253-3267 (US)
Priority Data:
60/199,970 27.04.2000 US
Title (EN) FULLERENE-BASED DRUGS TARGETED TO BONE
(FR) MEDICAMENTS A BASE DE FULLERENE CIBLES POUR LES OS
Abstract: front page image
(EN)A method for providing bone therapy in a patient in need of bone therapy comprises administering to the patient a pharmaceutically effective amount of a compound comprising a biologically inert carrier, a bone vector; and a therapeutic agent. The bone vector preferably comprises a bisphosphonate, the carrier preferably comprises a fullerene, and more preferably C¿60?, the therapeutic agent preferably comprises fluoride.
(FR)L'invention concerne une méthode de thérapie osseuse utilisée chez un patient nécessitant une thérapie osseuse, consistant à administrer au patient une quantité efficace d'un point de vue pharmaceutique d'un composé comprenant un excipient biologiquement inerte, un vecteur osseux et un agent thérapeutique. Le vecteur osseux comprend, de préférence, un bisphosphonate, l'excipient comprend, de préférence, un fullerène et, plus préférablement, C¿60?, et l'agent thérapeutique comprend du fluorure.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)